RECOMBINANT INTERLEUKIN-15 IS A THERAPEUTIC AGENT FOR THE TREATMENT OF AIRWAY HYPERACTIVITY, RESISTANCE (OBSTRUCTION) AND FIBROSIS IN CHRONIC ASTHMA

摘要

The invention method and composition disclosed herein generally related to the treatment and/or management of airway obstruction including resistance, hyperactivity and lung/esophageal fibrosis. We state that rIL-15 or IL-15 overexpressed by its agonist is a novel molecule for the treatment and management of pulmonary functional abnormalities like airway hyperreactivity, obstruction or fibrosis in chronic lung and esophageal inflammation. Chronic asthma is normally associated with the esophageal inflammation, a disease termed as eosinophilic esophagitis (EoE). In particularly invention is identifying the treatment strategy of airway hyperactivity, resistance, Obstruction and fibrosis in experimental asthma including the esophageal fibrosis in eosinophilic esophagitis. Our identified and preclinical tested rIL-15 protein or its super- agonist will be ready to be tested in the clinical trials of chronic asthma and eosinophilic esophagitis patients to treat airway hyperactivity resistance and fibrosis in patients.